Stock Events

Stock Events

Search...

Q32 Bio

$47.2

42

-$0.16-0.34% Today

Statistics

Day High

48.24

Day Low

46.54

52W High

53.79

52W Low

8.24

Volume

63,898

Avg. Volume

109,042

Mkt Cap

-

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

12NovExpected

Q4 2023

Q1 2024

Q2 2024

Next

-6.33

-4.55

-2.77

-1

Expected EPS

-1.31

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow QTTB. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

CRISPR Therapeutics

CRISPR Therapeutics is a leader in the development of gene-based therapies using CRISPR/Cas9 technology, directly competing with Homology's gene editing platform.

Editas Medicine

Editas Medicine operates in the gene editing space using CRISPR technology, similar to Homology Medicines, targeting genetic diseases.

Intellia Therapeutics

Intellia Therapeutics is another key player in CRISPR-based gene editing, competing in the same space as Homology Medicines for genetic disorder treatments.

Sangamo Therapeutics

Sangamo Therapeutics focuses on genomic medicine, including gene therapy and gene editing, making it a direct competitor in Homology's market.

bluebird bio specializes in gene therapies for severe genetic diseases and cancer, overlapping with Homology Medicines' therapeutic areas.

Biomarin Pharmaceutical

BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, competing in the genetic disease treatment market.

REGENXBIO is a biotechnology company focusing on the development, commercialization of gene therapies, directly competing with Homology's gene therapy approach.

Pfizer, through its acquisition of Bamboo Therapeutics and other initiatives, has entered the gene therapy space, making it a competitor in the broader market that Homology Medicines operates in.

Gilead Sciences

Gilead Sciences, with its acquisition of Kite Pharma and focus on cell therapies, competes in the advanced therapy medicinal products space, including gene therapies.

Vertex Pharmaceuticals

Vertex Pharmaceuticals, through its collaboration with CRISPR Therapeutics and focus on treating genetic diseases, competes in the same therapeutic areas as Homology Medicines.

Analyst Ratings

83$Average Price Target

The highest estimate is $100.

From 3 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

About

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Show more...

CEO

Arthur Tzianabos

Employees

41

Country

US

ISIN

US7469641051

Listings